WT1 and acute myeloid leukemia: Another small retrospective study performed by Malagola et al., including 24 AML patients with available WT1 measurement in PB samples before Allo-SCT, found that patients with WT1 < 5 copies had a significantly better OS and DFS than patients with WT1 ≥ 5 copies (3-year OS 54% vs. 0%, p = 0.03; 1-year LFS 63% vs. 20%, p = 0.02) [47].